^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CYT-0851

    i
    Other names: CYT-0851, CYT 0851
    Associations

    News

    Trials
    Company:
    Cyteir Therap
    Drug class:
    MCT1 inhibitor, RAD51 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=170, Active, not recruiting, Cyteir Therapeutics, Inc. | Trial completion date: Dec 2024 --> Apr 2025 | Trial primary completion date: Jul 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • MYC translocation • PGR negative • HER-2 negative + AR positive + ER positive • HER-2 negative + PGR positive
    |
    gemcitabine • Rituxan (rituximab) • capecitabine • bendamustine • CYT-0851
    over1year
    A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=170, Active, not recruiting, Cyteir Therapeutics, Inc. | Recruiting --> Active, not recruiting | N=320 --> 170 | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Feb 2023 --> Jul 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • MYC translocation • PGR negative
    |
    gemcitabine • Rituxan (rituximab) • capecitabine • bendamustine • CYT-0851
    over2years
    Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers. (ASCO 2022)
    CYT-0851 has demonstrated promising and broad clinical activity in a Ph 1 population of pts with advanced cancers. The safety profile is favorable as characterized by events that were infrequent, primarily Gr1/2, and reversible. Six expansion cohorts (DLBCL, Follicular Lymphoma, Myeloma, Pancreatic, Ovarian and Sarcoma) are enrolling to characterize activity at the RP2D.
    Clinical • P1/2 data
    |
    RAD51 (RAD51 Homolog A)
    |
    CYT-0851
    over2years
    A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=320, Recruiting, Cyteir Therapeutics, Inc. | Trial completion date: Oct 2022 --> Dec 2023 | Trial primary completion date: Sep 2021 --> Feb 2023
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • MYC translocation • PGR negative
    |
    gemcitabine • Rituxan (rituximab) • capecitabine • bendamustine • CYT-0851
    3years
    A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=320, Recruiting, Cyteir Therapeutics, Inc. | Trial completion date: Oct 2021 --> Oct 2022
    Clinical • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • MYC translocation • PGR negative
    |
    gemcitabine • Rituxan (rituximab) • bendamustine • CYT-0851
    over3years
    Preliminary Activity Seen with RAD51 Inhibitor. (PubMed, Cancer Discov)
    An investigational agent that inhibits RAD51-mediated homologous recombination DNA repair has shown preliminary signs of activity. In a phase I trial, CYT-0851 elicited three responses in patients with relapsed/refractory hematologic malignancies and advanced solid tumors and was associated with only mild side effects.
    Journal
    |
    RAD51 (RAD51 Homolog A)
    |
    CYT-0851
    over3years
    [VIRTUAL] First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers. (ASCO 2021)
    CYT-0851, a first-in-class inhibitor of RAD51-mediated HR, is well tolerated, with linear PK, target-directed PD effects and promising antitumor activity across different tumor types . CYT-0851 is the first DNA-damage repair (DDR) therapeutic with demonstrated clinical activity in both hematologic malignancies and solid tumors . Dose escalation continues to establish the RP2D, with planned expansion in 7 disease-specific cohorts in hematologic and solid cancers.
    Clinical • P1/2 data
    |
    RAD51 (RAD51 Homolog A)
    |
    CYT-0851